Skip to content

Sound Bioventures

Venture Capital Fund

  • CEO-Portal
  • Investor Portal
  • About
  • Team
  • Portfolio
  • Pipeline
  • Proposals
  • News
  • ESG
  • About
    • Team
    • Team Openings
    • Contact
    +
  • Portfolio
    • Aboleris
    • Artax Biopharma
    • Arthex
    • Breye Therapeutics
    • NephroDI
    • Teitur
    • Theolytics
    • VarmX
    +
  • Pipeline
  • Proposals
  • News
  • ESG
  • Press
  • Contact

Breye Therapeutics

All EventsFund articlesFund PRPortfolio articlesPortfolio PR

Breye Therapeutics Commences Oral Dosing of Danegaptide in Patients with Diabetic Retinopathy

2024.01.252024.05.13 / • Investigating potential for an oral treatment in diabetic retinopathy• First patient dosed in Phase 1b/2a clinical trial Copenhagen, Denmark, 25 January 2024 – Breye Therapeutics ApS (Breye), a ...

The oral therapeutic that could change our approach to retinal disease. An inflammation-based view of both ophthalmic and neurologic health

2023.11.032024.05.13 / Dr Burian said oral therapies can also function in conjunction with therapies currently on the market. In late July, biotech incubator Golgi Neurosciences S.r.l. and biopharmaceutical company Bre ...

Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer

2023.08.082024.05.13 / 25 July 2023 Collaboration to advance development of innovative oral small molecule therapeutics for retinal disorders Milan, Italy and Copenhagen, Denmark, 25 July 2023 – Golgi Neuroscien ...

Breye Therapeutics Strengthens Management Team and Board

2023.04.202024.10.07 / Industry veteran Dr. Peter Adamson, PhD appointed as Chief Scientific Officer Dr. Gabriela Burian, MD appointed to the Board of Directors Copenhagen, Denmark, 20 April 2023 – Breye Therapeuti ...
Brey Therapeutics

A visionary journey to innovate sight-preserving therapies

2023.01.252024.05.13 / Breye Therapeutics is all about the people. Whether it’s the company’s team or the patients whose eyesight they seek to protect, the focus is consistently on the human factor. It’s a value influenced ...
Brey Therapeutics

Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases

2022.11.102024.05.13 / Industry expert Ulrik Mouritzen M.D. appointed Chief Executive OfficerFunding to advance lead asset to phase 1b clinical trial and further build pipeline Copenhagen, Denmark, 10 November 2022 – Br ...
  1. Start
  2. News
  3. Breye Therapeutics

Sound Bioventures is a venture capital fund investing in about-to-be clinical and clinical stage private companies in Europe and the USA developing novel medicines that addresses unmet medical needs.

Company

  • About
  • Team
  • Portfolio
  • Team Openings
  • News
  • Contact
  • Proposals

Contact & Press

  • Sustainability & SFDR
  • Privacy Policy
  • Subscribe to our newsletter
  • Press

Sound Bioventures Management AB
Org.no: 559310-0026
Nordenskiöldsgatan 11a
211 19 Malmö

Visiting address:
Sound Bioventures Management ApS
c/o Ordnung
Strandvejen 125
DK-2900 Hellerup, Denmark
Directions

Phone
+45 (0)60 - 63 31 20

General inquiries
info@soundbioventures.com

LinkedIn

© Copyright 2024 Sound Bioventures Management AB. All rights reserved. | We use cookies to improve our services

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all